Palifermin
- Generic Name
- Palifermin
- Brand Names
- Kepivance
- Drug Type
- Biotech
- CAS Number
- 162394-19-6
- Unique Ingredient Identifier
- QMS40680K6
- Background
Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli.
Palifermin was granted FDA approval on 15 December 2004.
- Indication
For treatment of oral mucositis associated with chemotherapy and radiation therapy.
- Associated Conditions
- Oral Mucositis
Base Editing Hematopoietic Stem Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study
- Conditions
- CD40L-HyperIgM Syndrome
- Interventions
- Biological: Base-edited hematopoietic stem and progenitor cells
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-21
- Target Recruit Count
- 1
- Registration Number
- NCT06959771
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy
- Conditions
- X-linked Severe Combined ImmunodeficiencyX-SCIDXSCID
- Interventions
- Genetic: PlerixaforBiological: Base-edited hematopoietic stem and progenitor cells
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-05-18
- Target Recruit Count
- 18
- Registration Number
- NCT06851767
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
- Conditions
- Chronic Granulomatous Disease (CGD)X-Linked Chronic Granulomatous Disease
- Interventions
- Biological: Base-edited hematopoietic stem and progenitor cells
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2025-05-16
- Target Recruit Count
- 1
- Registration Number
- NCT06325709
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Conditions
- Myelodysplastic SyndromeAcute Lymphoblastic LeukemiaSecondary Acute Myeloid LeukemiaAcute Myeloid Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationRadiation: Total Lymphoid IrradiationRadiation: Total Marrow Irradiation
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT05139004
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplant RecipientHematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationRadiation: Fractionated Stereotactic Radiation Therapy
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT04177004
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency
- Conditions
- X-Linked Combined Immunodeficiency Diseases
- Interventions
- Biological: CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2019-12-04
- Target Recruit Count
- 13
- Registration Number
- NCT03315078
- Locations
- 🇺🇸
Laboratory of Host Defenses (LHD), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, United States
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
- Conditions
- Lymphoma
- Interventions
- Other: Oral Cryotherapy (ice chips)Biological: Stem Cell Infusion
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02961816
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT02589145
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
- Conditions
- Hodgkin's LymphomaNon-Hodgkin's LymphomaMyelodysplastic SyndromeMultiple MyelomaAcute Leukemia
- Interventions
- Drug: Conditioning chemotherapyDrug: TMSDrug: FLAGDrug: EPOCH-FProcedure: Hematopoietic stem cell transplant
- First Posted Date
- 2015-02-05
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT02356159
- Locations
- 🇺🇸
National Marrow Donor Program, Minneapolis, Minnesota, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2014-12-10
- Last Posted Date
- 2014-12-10
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 88
- Registration Number
- NCT02313792
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.